Cairo Pharmaceuticals results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit74.35 millionEGP · +25.6% vs the same period a year earlier
Total assets1.58 billionEGP · +22.6% vs the same period a year earlier
Shareholders' equity905 millionEGP · +21.4% vs the same period a year earlier
Operating cash flow51.58 millionEGP · +73.1% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q1 2025 was about 74.35 million EGP, up +25.6% from 59.17 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 1.58 billion EGP, and shareholders' equity about 905 million EGP.
- Operating cash flow for Q1 2025 was positive at 51.58 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit74.35 million59.17 million+25.6%
Gross profit136 million113 million+20.2%
Total assets1.58 billion1.29 billion+22.6%
Total liabilities678 million546 million+24.3%
Shareholders' equity905 million746 million+21.4%
Total liabilities and equity1.58 billion1.29 billion+22.6%
Operating cash flow51.58 million29.8 million+73.1%
Investing cash flow-32.34 million-15.21 million−112.7%
Financing cash flow-3.33 million67.5 million−104.9%
Net change in cash15.9 million82.1 million−80.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy